



ASX ANNOUNCEMENT

18 December 2018

**Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

Dear Sir / Madam,

Notification under sections 708A(5)(e) of the Corporations Act 2001 (Cth)

CardieX has issued an Appendix 3B with respect to the placement of 98,333,333 ordinary shares announced 6 December 2018 (**Placement**). Details of the Placement are set out in the announcement of 6 December 2018 and in the recently lodged Appendix 3B.

CardieX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the Placement, CardieX has issued 98,333,333 ordinary shares at the issue price of \$0.03 per share, raising approximately \$2,950,000 without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice:
 - (a) CardieX has complied with the provisions of Chapter 2M of the Act;
 - (b) CardieX has complied with section 674 of the Act; and
 - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

Yours faithfully,

A handwritten signature in blue ink, appearing to read "Jarrod White", with a large, stylized flourish at the end.

Jarrod White
Company Secretary | Chief Financial Officer

Chief Financial Officer

Jarrod White

jwhite@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

**About CardieX**

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.